Management Change/Compensation Form 8 K

Item 2.01 Completion of Acquisition or Disposition of Assets.

On February 2, 2024 (the "Petition Date"), DMK Pharmaceuticals Corporation (the "Company") and certain of its direct and indirect subsidiaries (collectively, the "Company Parties") commenced bankruptcy cases (the "Chapter 11 Cases") by filing voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court").

On May 16, 2024, pursuant to an agreement approved by the Bankruptcy Court, the Company sold all of its assets relating to its ZIMHI products and business to zmi pharma inc. for $3,170,600.